Dyno Therapeutics announces that Astellas exercised its skeletal-muscle capsid option under their 2021 deal. Dyno says the exercise validates its AI-powered technology for biological sequence design.
Dyno and Trisk Bio announce a strategic manufacturing partnership, with Trisk Bio named the first manufacturing partner in Dyno’s expanded Frontiers Program. The partnership will supply vectors toward clinical testing.
Dyno Therapeutics and Trisk Bio announce a strategic manufacturing partnership through Dyno’s expanded Frontiers Program. Trisk Bio is the program’s first manufacturing partner and will supply Dyno vectors toward clinical testing.
Roche expands its central nervous system partnership with Dyno Therapeutics in a potential gene therapy deal targeting neurological diseases. Under the agreement, Roche pays $50 million upfront and could provide more than $1 billion in milestone payments, plus royalties, for Dyno’s AI-designed AAV vectors.
